ANI Pharma (ANIP) Misses Q4 EPS by 10c, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
ANI Pharmaceuticals Reports Full Year and Fourth Quarter 2019 Results, Provides 2020 Guidance and Remains on Track to Submit Cortrophin® Gel sNDA to FDA in March 2020
February 27, 2020 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2020 /PRNewswire/ --
For the full year ended December 31, 2019:
Record net revenues of $206.5 million, an increase of 2.5% versus 2018 GAAP net income of $6.1 million and diluted GAAP earnings per share of $0.50 Adjusted non-GAAP EBITDA of $83.2 million Adjusted non-GAAP diluted earnings per share of $5.06For the fourth quarter 2019:
Net revenues of $48.0 million versus $57.1 million in 2018 GAAP net loss of $4.8 million and diluted GAAP loss per share of $0.41 Adjusted non-GAAP EBITDA of $17.4 million... More